Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096754 | 0.80 | ABL1 (0.44) | SMN1; SMN2ALDH1A1MAPTCA12CA9 | |
| SCHEMBL15064004 | 0.72 | — | — | |
| SCHEMBL455305 | 0.69 | — | — | |
| SCHEMBL6907987 | 0.69 | — | — | |
| SCHEMBL14882628 | 0.69 | ALOX15 (0.47) | SMN1; SMN2TSHRCASP1MAOBMAOA | |
| SCHEMBL1096053 | 0.69 | — | — | |
| SCHEMBL29533520 | 0.68 | ALDH1A1 (0.50) | SMN1; SMN2TSHRCASP1MAOBMAOA | |
| SCHEMBL332423 | 0.68 | ALDH1A1 (0.50) | SMN1; SMN2TSHRCASP1MAOBMAOA | |
| SCHEMBL10575131 | 0.68 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRCASP1MAOBALDH1A1 | |
| SCHEMBL29384783 | 0.67 | TSHR (0.65) | SMN1; SMN2TSHRCASP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871760-B2 | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| CN-102639532-A | Fused triazole amines as P2X7 modulators | HOFFMANN LA ROCHE | 2012-08-15 | — | — | CN | disclosed |
| EP-2480545-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2459541-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| CN-102471284-A | Dihydropyrimidone amides as P2X7 modulators | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | disclosed |
| US-8153808-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2011033055-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-03-24 | — | — | US | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
| WO-2011012592-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072605-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072647-A2 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160387-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | SMN1; SMN2 2596/4885TSHR 814/4885CASP1 896/4885 |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | P2RX3, P2RX1, P2RY1 | SMN1; SMN2 2622/4885TSHR 530/4885CASP1 632/4885 |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | SMN1; SMN2 3020/4885TSHR 462/4885CASP1 576/4885 |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | P2RX3, P2RX7, P2RX1 | SMN1; SMN2 3496/4885TSHR 357/4885CASP1 418/4885 |
| US-20100160387-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | SMN1; SMN2 2103/4885TSHR 862/4885CASP1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.